Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Boehringer Ingelheim International Gmbh patents (2018 archive)


Recent patent applications related to Boehringer Ingelheim International Gmbh. Boehringer Ingelheim International Gmbh is listed as an Agent/Assignee. Note: Boehringer Ingelheim International Gmbh may have other listings under different names/spellings. We're not affiliated with Boehringer Ingelheim International Gmbh, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Boehringer Ingelheim International Gmbh-related inventors


Anti il-36r antibodies combination therapy

. . . . The present invention relates to anti-il-36r binding compounds, in particular new anti-il-36r antibodies and therapeutic and diagnostic methods and compositions for using the same.. . ... Boehringer Ingelheim International Gmbh

Treatment for diabetes in patients inappropriate for metformin therapy

The present invention relates to the finding that certain dpp-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.. . ... Boehringer Ingelheim International Gmbh

Cardio- and renoprotective antidiabetic therapy

The present invention relates to a certain dpp-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.. . ... Boehringer Ingelheim International Gmbh

Nebulizer

. . . . . . . . A nebulizer is proposed which comprises a blocking device for blocking opening of the nebulizer in a tensioned state. The nebulizer comprises preferably an indicator device for indicating a tensioned state of the nebulizer. ... Boehringer Ingelheim International Gmbh

Administration of ethyl 3-[(2-{[4-(hexyloxycarbonyl-aminoiminomethyl)phenyl-amino]methyl}-1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate

The invention relates to a new administration form for the oral application of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate and the pharmacologically acceptable salts thereof.. . ... Boehringer Ingelheim International Gmbh

Pharmaceutical composition, methods for treating and uses thereof

The invention relates to the treatment or prevention of renal impairment and/or complications using a sglt-2 inhibitor, for example in patients diagnosed with metabolic disorders and related conditions.. . ... Boehringer Ingelheim International Gmbh

Therapeutic and diagnostic target for cancer comprising dll3 binding reagents

. . The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer, such as lung cancer, pancreatic cancer and skin cancer, for monitoring the effectiveness of cancer, such as lung cancer, pancreatic cancer and skin cancer treatment, and for drug development.. . ... Boehringer Ingelheim International Gmbh

Vegf-binding molecules

Vegf-binding molecules, preferably vegf-binding immunoglobulin single variable domains like vhhs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with vegf-mediated effects on angiogenesis. Nucleic acids encoding vegf-binding molecules, host cells and methods for preparing same.. ... Boehringer Ingelheim International Gmbh

Pharmaceutical composition, methods for treating and uses thereof

The present invention relates to certain sglt-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (ckd).. . ... Boehringer Ingelheim International Gmbh

Pharmaceutical composition, methods for treating and uses thereof

. . The invention relates to a pharmaceutical composition according to the claim 1 comprising an sglt2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions. ... Boehringer Ingelheim International Gmbh

Anti cd37 antibodies

. . Chimeric and humanized anti-cd37 antibodies and pharmaceutical compositions containing them are useful for the treatment of b cell malignancies and autoimmune and inflammatory diseases that involve b cells in their pathology.. . ... Boehringer Ingelheim International Gmbh

A general process for the preparation of 6-substituted or 5,6-disubstituted derivatives of 2-amino-isonicotinic acid

This invention relates to a novel synthetic method for the preparation of 6-substituted or 5,6-disubstituted derivatives of 2-amino-isonicotinic acid.. . ... Boehringer Ingelheim International Gmbh

Pharmaceutical compositions

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a dpp-4 inhibitor drug and/or a sglt-2 inhibitor drug, and metformin xr, processes for the preparation thereof, and their use to treat certain diseases.. . ... Boehringer Ingelheim International Gmbh

Binding molecules for the treatment of cancer

This invention relates to binding molecules that bind specifically to tnf-related apoptosis-inducing ligand receptor 2 (trailr2) and cadherin-17 (cdh17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.. . ... Boehringer Ingelheim International Gmbh

06/28/18 / #20180179207

Process for the preparation of a xanthine-based compound

This invention relates to a method for preparation of a xanthine-based compound, as well as to intermediates useful in such preparation.. . ... Boehringer Ingelheim International Gmbh

06/28/18 / #20180179142

Novel process for the preparation of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione

This invention relates to methods for the synthesis of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione which are useful as intermediates in the manufacture of pharmaceutically active ingredients.. . ... Boehringer Ingelheim International Gmbh

06/28/18 / #20180177794

Methods of treatment and pharmaceutical compositions using an sglt-2 inhibitor and a neuroleptic agent

The invention relates to methods for preventing, slowing the progression of, delaying or treating metabolic disorders induced in patients by the treatment with neuroleptic agents comprising administering to the patients an sglt2 inhibitor.. . ... Boehringer Ingelheim International Gmbh

06/21/18 / #20180171279

Cell-controlled perfusion in continuous culture

Methods of protein production in continuous perfusion mammalian cell culture bioreactors are provided. Methods for continuous perfusion culture by allowing cells to self-regulate the rate of addition of perfusion medium to the bioreactor via a ph change are presented. ... Boehringer Ingelheim International Gmbh

06/21/18 / #20180169126

Pharmaceutical composition, methods for treating and uses thereof

The present invention relates to certain sglt-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.. . ... Boehringer Ingelheim International Gmbh

06/07/18 / #20180155377

Novel chiral dihydrobenzoazaphosphole ligands and synthesis thereof

This invention relates to novel phosphorous ligands useful for organic transformations. Methods of making and using the ligands in organic synthesis are described. ... Boehringer Ingelheim International Gmbh

06/07/18 / #20180155375

Novel chiral dihydrobenzooxaphosphole ligands and synthesis thereof

This invention relates to novel phosphorous ligands useful for organic transformations. Methods of making and using the ligands in organic synthesis are described. ... Boehringer Ingelheim International Gmbh

05/24/18 / #20180141948

New 5,8-dimethyl-9-phenyl-5,8-dihydro-6h-pyrazolo[3,4-h]quinazolin-2-yl)-(1h-pyrazol-3-yl)-amines and derivatives as igf-1r/ir inhibitors

. . . . The present invention encompasses compounds of formula (i) wherein the groups a, r and q are defined in claim 1, their use as inhibitors of igf-1 r, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.. . ... Boehringer Ingelheim International Gmbh

05/17/18 / #20180136155

Method and device for determination of water content

A method for determining water content of a preferably solid pharmaceutical preparation/sample, wherein at least two electrodes are brought into direct contact with the pharmaceutical preparation/sample in a measurement chamber such that the electrodes are electrically connected to one another via the pharmaceutical preparation/sample, and wherein a resistance of the pharmaceutical preparation/sample is determined by means of the electrodes and the water content and/or the sample quality of the pharmaceutical preparation/sample is determined with the ohmic resistance.. . ... Boehringer Ingelheim International Gmbh

05/17/18 / #20180134720

Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide

The invention relates to spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (i) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.. ... Boehringer Ingelheim International Gmbh

05/10/18 / #20180127474

Novel anti-baff antibodies

The present invention relates to anti-baff antibody molecules, including novel humanized anti-baff antibodies, therapeutic and diagnostic methods and compositions for using the same.. . ... Boehringer Ingelheim International Gmbh

05/10/18 / #20180125813

Pharmaceutical composition, methods for treating and uses thereof

The present invention relates to methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease comprising administering empagliflozin to the patient.. . ... Boehringer Ingelheim International Gmbh

05/03/18 / #20180119191

Cell engineering using rnas

The invention concerns the field of cell culture technology. It concerns rna having a specific sequence, expression vectors encoding said rna, production host cell lines comprising said rna, and methods of producing recombinant biopharmaceutical products using engineered host cell with altered levels of said rnas, such as small non-coding rnas, preferably micrornas (mirnas). ... Boehringer Ingelheim International Gmbh

04/19/18 / #20180105588

Methods of treating diseases

. . This invention generally relates to methods for the treatment of il-23 related diseases, in particular inflammatory diseases, such as crohn's disease, utilizing anti-il-23a antibodies.. . ... Boehringer Ingelheim International Gmbh

04/19/18 / #20180105512

Substituted benzimidazolium compounds useful in the treatment of respiratory diseases

The present invention relates to compounds of formula (i), or the tautomers or pharmacologically acceptable acid addition salts thereof, characterized by a topological polar surface area value (tpsa) of at least 145, wherein r1, r2, r3, r4, x, and z− have one of the meanings as defined in the specification, to the use of compounds of formula (i) as a medicament, to pharmaceutical composition comprising at least one compound of formula (i), as well as to medicament combinations containing one or more compounds of formula (i).. . ... Boehringer Ingelheim International Gmbh

04/19/18 / #20180104268

Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction

The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a sglt2 inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus or type 2 diabetes mellitus characterized in that in addition to the treatment of erectile dysfunction a sglt2 inhibitor is administered to the patient. ... Boehringer Ingelheim International Gmbh

04/19/18 / #20180104249

Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof

The present invention relates to pharmaceutical compositions of linagliptin, pharmaceutical dosage forms, their preparation, their use and methods for treating metabolic disorders.. . ... Boehringer Ingelheim International Gmbh

04/12/18 / #20180099969

Polymorphs

The invention relates to polymorphous crystal modifications of a dpp-iv inhibitor, the preparation thereof and the use thereof for preparing a medicament.. . ... Boehringer Ingelheim International Gmbh

04/05/18 / #20180094038

Acylated glucagon analogue

. . The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. ... Boehringer Ingelheim International Gmbh

03/15/18 / #20180071366

Amylin analogues

. . . . . . . . . . . . The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.. ... Boehringer Ingelheim International Gmbh

03/08/18 / #20180064811

Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents

The present invention relates to pharmaceutical combinations cd33 antibodies and de-methylating agents for use in treating diseases like mds and cancer, especially aml.. . ... Boehringer Ingelheim International Gmbh

02/15/18 / #20180044335

New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9

. . The present invention encompasses compounds of general formula (i) wherein the groups r1 to r9, x1 and x2 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, e.g. ... Boehringer Ingelheim International Gmbh

02/01/18 / #20180030141

Cx3cr1-binding polypeptides

. . . . The present invention relates to cx3cr1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.. ... Boehringer Ingelheim International Gmbh

02/01/18 / #20180028500

New azabenzimidazole derivatives as agonists of the amp-activated protein kinase

The present invention relates to compounds of general formula i, wherein the group r1, x and y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the amp-activated protein kinase (ampk) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.. ... Boehringer Ingelheim International Gmbh

02/01/18 / #20180028451

Immeadiate release oral tablet

A process for the preparation of an immediate release tablet comprising the antihypertensive telmisartan and the tablet obtained by the process.. . ... Boehringer Ingelheim International Gmbh

01/11/18 / #20180009887

Methods of treating diseases

. . . . This invention generally relates to methods for the treatment of respiratory diseases, such as asthma, utilizing anti-il-23a antibodies.. . ... Boehringer Ingelheim International Gmbh

01/11/18 / #20180009789

Substituted benzimidazolium compounds useful in the treatment of respiratory diseases

The present invention relates to compounds of formula (i), or the tautomers or pharmacologically acceptable acid addition salts thereof, wherein r1, r2, r3, r4, x, and z have one of the meanings as defined in the specification, to the use of compounds of formula (i) as a medicament, to pharmaceutical composition comprising at least one compound of formula (i), as well as to medicament combinations containing one or more compounds of formula (i).. . ... Boehringer Ingelheim International Gmbh

01/04/18 / #20180002349

New azabenzimidazole derivatives

The present invention relates to compounds of general formula (i), wherein r1, r2, r3, a1, a2, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the amp-activated protein kinase (ampk) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.. ... Boehringer Ingelheim International Gmbh

01/04/18 / #20180002314

2-(pyrazin-2-ylcarbonylaminomethyl) benzimidazolium compounds as epithelial sodium channel inhibitors

The present invention relates to compounds of formula (i) or the tautomers or pharmacologically acceptable acid addition salts thereof, characterized by a topological polar surface area value (tpsa) of at least 145, wherein r1, r2, r3, r4, x, and z− have one of the meanings as defined in the specification, to the use of compounds of formula (i) as medicaments, to pharmaceutical compositions comprising at least one compound of formula (i), as well as to medicament combinations containing one or more compounds of formula (i). The compounds are enac inhibitors useful for the treatment of respiratory diseases and allergic diseases of the airways.. ... Boehringer Ingelheim International Gmbh

01/04/18 / #20180002312

Tetra- and pentasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases

The present invention relates to compounds of formula (i), or the tautomers or pharmacologically acceptable acid addition salts thereof, wherein r1, r2, r3, r4, x, and z have one of the meanings as defined in the specification, to the use of compounds of formula (i) as a medicament, to pharmaceutical composition comprising at least one compound of formula (i), as well as to medicament combinations containing one or more compounds of formula (i).. . ... Boehringer Ingelheim International Gmbh

01/04/18 / #20180000730

Oral disintegrating tablet

A process for the preparation of an oral disintegrating tablet comprising the antihypertensive telmisartan and the tablet obtained by the process.. . ... Boehringer Ingelheim International Gmbh








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Boehringer Ingelheim International Gmbh in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Boehringer Ingelheim International Gmbh with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###